Terms: = Brain cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Prognosis
102 results:
1. Clinical Management of Patients with Non-Small Cell Lung cancer, brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of Immunohistochemical Expression of alk-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
[TBL] [Abstract] [Full Text] [Related]
3. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-alk and alk-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract] [Full Text] [Related]
4. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (alk)-positive lung cancer and multiple brain metastases.
Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
[TBL] [Abstract] [Full Text] [Related]
5. Validation of the alk-brain Prognostic Index for patients with alk-rearranged lung cancer and brain metastases.
Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
ESMO Open; 2023 Dec; 8(6):102069. PubMed ID: 37988952
[TBL] [Abstract] [Full Text] [Related]
6. Stroke as initial manifestation of non-small cell lung cancer with Trousseau syndrome.
Hong W; Zhang T; Shan C; Li H; Lin T; Liu D; Zhen J; Li J; Lai M; Zhou Z; Zhou C; Zhou M; Wang M; Cai L; Wen L
BMC Cancer; 2023 Nov; 23(1):1096. PubMed ID: 37950224
[TBL] [Abstract] [Full Text] [Related]
7. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression.
Pflug KM; Lee DW; Tripathi A; Bankaitis VA; Burgess K; Sitcheran R
Mol Pharm; 2023 Dec; 20(12):6140-6150. PubMed ID: 37939020
[TBL] [Abstract] [Full Text] [Related]
8. Transformation of NSCLC to SCLC harboring EML4-alk fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
9. Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
Zhu Z; Liu Y; Xu H; Ning H; Xia Y; Shen L
J Cardiothorac Surg; 2023 Aug; 18(1):254. PubMed ID: 37653509
[TBL] [Abstract] [Full Text] [Related]
10. Podcast on Lorlatinib as a First-Line Treatment Option for Patients with alk-Positive Metastatic NSCLC with brain Metastasis.
Liu G; Lam VK
Adv Ther; 2023 Oct; 40(10):4117-4126. PubMed ID: 37573276
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic impact of EGFR/alk alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy.
Oyoshi H; Hirata H; Hirano Y; Zenda S; Zhou Y; Tomizawa K; Fujisawa T; Nakamura M; Hojo H; Motegi A; Kageyama SI; Zenke Y; Goto K; Ishihara S; Naganawa S; Akimoto T
Clin Exp Metastasis; 2023 Oct; 40(5):407-413. PubMed ID: 37468822
[TBL] [Abstract] [Full Text] [Related]
12. Genomic Alterations and the Incidence of brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis.
Gillespie CS; Mustafa MA; Richardson GE; Alam AM; Lee KS; Hughes DM; Escriu C; Zakaria R
J Thorac Oncol; 2023 Dec; 18(12):1703-1713. PubMed ID: 37392903
[TBL] [Abstract] [Full Text] [Related]
13. Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in alk-positive lung cancer with brain metastases.
Shi L; Guo L; Tao H; Meng Q; Tong L; Tang J; Li K; Zhang S; Liu Z
Thorac Cancer; 2023 Jul; 14(19):1883-1893. PubMed ID: 37287428
[TBL] [Abstract] [Full Text] [Related]
14. Expression of Anaplastic Lymphoma Kinase (alk) in glioma and possible clinical correlations. A retrospective institutional study.
Azab MA
Cancer Treat Res Commun; 2023; 36():100703. PubMed ID: 37271069
[TBL] [Abstract] [Full Text] [Related]
15. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (alk)‑Positive Non‑Small‑Cell Lung cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract] [Full Text] [Related]
16. Effectiveness of alk inhibitors in treatment of CNS metastases in NSCLC patients.
Gil M; Knetki-Wróblewska M; Niziński P; Strzemski M; Krawczyk P
Ann Med; 2023 Dec; 55(1):1018-1028. PubMed ID: 36896848
[TBL] [Abstract] [Full Text] [Related]
17. Heterogeneity of tumor immune microenvironment of EGFR/alk-positive tumors versus EGFR/alk-negative tumors in resected brain metastases from lung adenocarcinoma.
Xiao G; Li L; Tanzhu G; Liu Z; Gao X; Wan X; Xiao D; Chen L; Xia X; Zhou R
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868569
[TBL] [Abstract] [Full Text] [Related]
18. Survival Benefits of Radiotherapy and Surgery in Lung cancer brain Metastases with Poor prognosis Factors.
Liang L; Wang Z; Duan H; He Z; Lu J; Jiang X; Hu H; Li C; Yu C; Zhong S; Cui R; Guo X; Deng M; Chen Y; Du X; Wu S; Chen L; Mou Y
Curr Oncol; 2023 Feb; 30(2):2227-2236. PubMed ID: 36826133
[TBL] [Abstract] [Full Text] [Related]
19. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
[TBL] [Abstract] [Full Text] [Related]
20. Current treatment approaches for brain metastases in
Rossi S; Marinello A; Pagliaro A; Franceschini D; Navarria P; Finocchiaro G; Toschi L; Scorsetti M; Santoro A
Expert Rev Anticancer Ther; 2023 Jan; 23(1):29-41. PubMed ID: 36548111
[TBL] [Abstract] [Full Text] [Related]
[Next]
